Drugs in R & D

, Volume 4, Issue 2, pp 113–114 | Cite as

Alpha-Antitrypsin — Alpha Therapeutic Corporation

AAT — Alpha Therapeutic Corporation, Alpha-1 Proteinase Inhibitor — Alpha Therapeutic Corporation, Alpha-1-Antitrypsin — Alpha Therapeutic Corporation, Aralast™, Respitin™
Adis R&D Profile


Airflow Obstruction Bioequivalence Study Antitrypsin Deficiency Profile Therapeutics Initial Treatment Period 


  1. 1.
    Baxter Healthcare Corporation. Baxter to Acquire Alpha-1 Antitrypsin and Other Assets From Alpha Therapeutic Corporation. Media Release: 20 Dec 2002. Available from URL: http://www.baxter.com Google Scholar
  2. 2.
    Alpha Therapeutic Corporation. Alpha Therapeutic Corporation Announces Development Agreement for New Inhaled Therapy for Genetic Emphysema Media Release: 1 Aug 2002. Available from URL: http://www.alphather.com
  3. 3.
    Alpha Therapeutic Corporation, Baxter Healthcare Corporation. Alpha Therapeutic Corporation Receives FDA Approval for Aralast™ Alpha-1 Proteinase Inhibitor. Media Release: 9 Jan 2003. Available from URL: http://www.alphather.com Google Scholar
  4. 4.
    Stoller JK, Rouhani F, Brantly M, et al. Biochemical efficacy and safety of a new pooled human plasma alpha-1-antitrypsin, Respitin. Chest. 122: 66–74, Jul 2002PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2003

Personalised recommendations